Last reviewed · How we verify

Ropivacaïne

Nantes University Hospital · FDA-approved active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgery and acute pain management, Peripheral nerve blocks, Epidural and spinal anesthesia.

At a glance

Generic nameRopivacaïne
SponsorNantes University Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers, thereby stabilizing the neuronal membrane and preventing depolarization. This action blocks the conduction of nerve impulses in sensory, motor, and autonomic fibers depending on the concentration and route of administration. It is an amide-type local anesthetic with a long duration of action and relatively low systemic toxicity compared to some alternatives.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: